Scottish scientists to lead world's first study on antibiotic resistance in pets
Based in Inverness, the research group from Scotland's Rural College (SRUC) will work with the UK Government's Veterinary Medicines Directorate (VMD) to launch a new surveillance programme aimed at detecting antimicrobial resistance (AMR) in healthy pets.
The groundbreaking pilot project will be the first of its kind anywhere in the world to monitor AMR in a country's pet population.
It will also play a key role in reducing infection risks for both animals and their owners.Around half of adults in the UK own a pet, meaning humans and animals often live in close contact. That makes it easier for resistant bacteria to spread between them and potentially makes infections harder to treat or, in some cases, untreatable.Scientists say that while antibiotic use is sometimes essential, it should be limited to when it's truly needed to avoid contributing to resistance.The new study will build on existing animal AMR surveillance work, which until now has only focused on a small number of unwell animals. It will be the first time that healthy pets across the UK are part of a national effort to track resistance levels.
Professor John Berezowski, based at SRUC's Rural and Veterinary Innovation Centre in Inverness, said: 'This initiative is critical for a better understanding of the transmission and maintenance of AMR in our pets.
'Our experts have worked hard to develop a practical AMR surveillance system. We plan to follow a team approach, working with pet owners and their vets as we explore how best to collect samples for surveillance throughout the UK.'
Abi Seager, chief executive of the VMD, added: 'Antimicrobial resistance is one of the most serious global health threats we face.
'I am proud to launch this ground-breaking AMR surveillance project in healthy cats and dogs with SRUC, who have a proven track record in establishing surveillance programmes from the ground up, and this new study is a truly One Health intervention to tackle AMR.'
The World Health Organisation ranks AMR among the top public health threats globally, and the findings from this project could help shape future policies on antibiotic use in animals.
Get all the latest news from around the country Follow STV News
Scan the QR code on your mobile device for all the latest news from around the country
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Telegraph
a day ago
- Telegraph
Labour's decision to close the Fleming Fund is a false economy that puts our national security at risk
Health emergencies rarely respect borders or budgets. As I write, the world is facing an antibiotic emergency, with bacteria rapidly evolving resistance to the treatments we depend on to counter infectious diseases. Without effective antibiotic treatments, global health and the global economy are defenceless against the likes of pneumonia and sepsis. Antibiotics are the infrastructure of modern medicine, making chemotherapy, caesarean sections and hip replacements possible. More than 1.1million people die across the world every year because of antibiotic resistance, including 35,000 in the UK alone. These trends are increasing and inter-generational, with deaths in children tripling in the last three years. For the last decade, the UK has been at the forefront of global efforts to tackle the wider threat posed by antimicrobial resistance (AMR). While antibiotic resistance poses the single biggest threat to modern medicine, AMR points to a serious problem for all types of antimicrobial agents – antifungals, antivirals, and antiparasitics – threatening to reverse all the significant gains we've made against HIV, malaria, and tuberculosis. The UK's Fleming Fund has been a bulwark against such threats: building laboratory capacity in 25 low- and-middle-countries to detect emerging AMR outbreaks, allowing for proactive, data-driven responses before they escalate into global crises. Among many other things, the Fleming Fund has tripled the genomic sequencing capacity across the entire African continent – which even pivoted to detect Covid-19 variants. The UK government's decision to shut down the Fleming Fund is a false economy and directly puts our national security at risk. It will cost lives, as well as precious GDP that could be spent on frontline NHS services. If we are to learn any lessons at all from Covid-19, it should be that we cannot afford to cut corners when it comes to preventing and preparing for inevitable pathogenic threats. Bold investment to protect against AMR Decisions made today will directly impact our ability to counter and contain AMR pandemics in the very near future. When I was Chancellor in 2023, the Treasury recognised the economic health ramifications of AMR, and the UK government commissioned economic studies to better understand the risks and opportunities. The Institute of Health Metrics and Evaluation found that if AMR resistance accelerates in line with poorer-performing countries, the world faces an additional seven million deaths globally by 2050. The Center for Global Development then estimated that economically, this would wipe $1.7 trillion annually off global GDP by 2050 and it will cost $175 billion extra a year for health systems to treat people. Country-level estimates released recently estimate that the British economy would be $59 billion smaller in this scenario and the UK would spend an additional $2.8 billion a year treating superbugs. $296 billion and $188 billion would be wiped off the US and EU economies respectively. In contrast, this research shows that there would be large economic benefits to the UK and elsewhere if we invest in improving the treatment of infections. With the UK economy facing significant challenges and the NHS workforce facing rising pressures, now is the time to act boldly and invest proactively to protect against AMR. Whilst the UK alone cannot solve AMR, the UK can and should leverage its world-leading technical expertise and diplomatic leadership through the Fleming Fund, its Special Envoy on AMR, Dame Sally Davies, and other global investments in AMR. Even in a world where only 0.3 per cent of gross national income (GNI) is earmarked for international aid funding, there must be a budget line for AMR. If we are to drive economic growth and build resilience against health threats at home and abroad, we need decisive action with investments that put health security first. With an evolved Fleming Fund, we can mitigate against the worst effects of AMR by supporting research and development of new antibiotics, increasing access to treatments in countries where lack of access accelerates resistance, embedding large-scale education and training programmes to ensure the sustainable and responsible use of existing antibiotics, and harnessing AI for diagnostic tests and surveillance for the UK and the countries most severely impacted by AMR. A world without the Fleming Fund puts even greater pressure on UK government and the life sciences sector to find new ways to prepare for the pandemics we already detect and those we are yet to detect, to safeguard UK health and economic security. Now is the time for the government to step up.
Telegraph
a day ago
- Telegraph
Antimicrobial resistance and the fight to prevent a real-life The Last of Us
In the popular zombie-apocalypse TV show The Last of Us, humans become infected with parasitic fungi, causing a blooming fungal amour to sprout from their skulls. It's gripping TV but in the real-world, deaths from fungal infections have doubled in the last decade and drug-resistant fungi are showing an alarming upward trajectory, making this fictional threat feel uncomfortably close to reality. Antimicrobial resistance (AMR), when fungi, bacteria, viruses and parasites evolve to resist the antimicrobial medicines designed to kill them, is quickly accelerating, fuelling a 'silent pandemic'. Since 1990, at least one million people have died from AMR every year. In the next 25 years, it could cause the deaths of almost 40 million people. Low- and middle-income countries like my own, Nigeria, face a dual challenge. First, a lack of access to antimicrobials leads to more deaths from AMR and actually makes the resistance problem worse. And overuse of antimicrobials in other parts of the world – particularly in healthcare and agriculture – is also fuelling resistance. The result is not just a health crisis but a development emergency. A recent study found that AMR economically hits low- and middle-income countries the hardest. Today, it costs approximately $66 billion and this is set to rise to $159 billion if action is not taken to effectively curb it. In the midst of this worsening crisis, the UK Government recently announced that it is shutting the Fleming Fund – named after the discoverer of penicillin and a key player in the fight against AMR. While bad for UK science and the broader global effort to tackle AMR, it now falls on others to take up the baton to tackle one of the world's most existential threats. The good news is that new leadership is emerging in the countries hit the hardest. This month, the Government of Nigeria announced it will host the fifth Global High-Level Ministerial Conference on AMR in 2026 – the first time the event will be held in Africa. While promising developments, such as the antibiotic zosurabalpin, currently undergoing human trials, or the use of artificial intelligence in drug discovery, give reason for cautious optimism, there is much more to be done to ensure that life-saving treatments are available to the people that need them. First, we must prioritise access to quality diagnostic tools, our first line of defence against AMR. Diagnostics ensure that antimicrobials are used appropriately, increasing patients' chances of recovery while slowing resistance. They also protect new discoveries by preventing unnecessary use. Diagnostics are not just critical for individual patients, they are vital for tracking resistance patterns across animal, and environmental health; sectors which are deeply interlinked in our fight against AMR. Today most of the world is fighting AMR without access to diagnostics. Without them, we're not just under-equipped – we're fighting blind. Second, we must expand access to antimicrobials, create the market conditions needed for further drug development, and ensure that every country implements and enforces a national action plan for AMR. Research in the Lancet across eight low- and middle-income countries found less than seven percent of people with drug-resistant bacterial infections could access the antibiotics they needed. Without these medicines, both patients and the wider community are at risk, as pathogens spread and evolve. Third, we must dramatically increase investment in innovation and strengthen the fragile antimicrobial pipeline. New antimicrobials are urgently needed to meet growing global demand and unmet needs. At the fourth Global High-Level Ministerial Conference on AMR in Jeddah, Saudi Arabia, leaders acknowledged the weak pipeline for new antibiotics and the market failures holding back development. The economic model is broken. Antibiotic research is costly, slow, and high-risk: for new classes of antibiotics, only one in 30 candidates will reach patients, and these are often reserved as a last resort. Government and industry must act urgently and ambitiously to reform the market to mobilise innovation. We need new economic models that reward long-term public health benefits, not just short-term profits. Finally, diagnostic and antimicrobial access and innovations must be backed by strong national action plans. At the second high level meeting on AMR at the 79th United Nations General Assembly, global leaders committed to developing or implementing national AMR action plans. At that time, while 178 countries had developed multi-sectoral national action plans, only 68 percent were implementing these plans. Last year, Nigeria launched its second national action plan on AMR, building on efforts to curb overuse and misuse of antimicrobials across human and animal health. But as we have learnt from Covid-19, pathogens do not know borders. Containing AMR demands global, coordinated action and accountability. We're not in the apocalyptic world of The Last of Us just yet but AMR has long been claiming lives, and is a blight on our health systems and economies. The decisive action we take in the next year will be key to preventing the unravelling of modern medicine.
Telegraph
a day ago
- Telegraph
The UK no longer a ‘reliable partner' in fight against AMR, says City's superbug tsar
The UK is no longer a 'reliable partner' in the global fight against antimicrobial resistance, according to the architect of the government's superbugs strategy. In an interview with The Telegraph, Lord Jim O'Neill said he was 'disillusioned' over the government's decision to shelve The Fleming Fund, a £265 million project aimed at tackling antimicrobial resistance (AMR) in 25 African and Asian countries. 'It sends a message that the UK can't be really regarded as reliable on these big picture, hugely important global health challenges,' Lord O'Neill told The Telegraph. Lord O'Neil, an economist and former chairman of Goldman Sachs, led the 2014 Review on Antimicrobial Resistance on behalf of the British Government, warning there could be 10 million people around the world dying from AMR-related illnesses by 2050 without action. Since the report was published more than a decade ago there has been cross-party support for prioritising the fight against superbugs but last month Labour announced it was closing the Fleming Fund, the UK flagship project in the area. 'It sends this really bad symbolic message around the world ... I'm still a bit stumped as to the lack of awareness of what the consequences are,' Lord O'Neill told the Telegraph. The fund was launched in 2015 following the publication of Lord O'Neil's Review and with the backing of the then Chief Medical Officer Dame Sally Davies. Britain has since become a world leader in the science behind AMR, the Fleming Fund marking a large part of the UK's contributions to the field. AMR is fuelled by the misuse and overuse of antibiotics and other antimicrobials in humans and agriculture and is described by The World Health Organization (WHO) as 'one of the top global public health and development threats.' Already, at least 32,000 people in the UK die of a resistant infection every year, prompting experts to call it a 'silent pandemic'. In February, a review from the National Audit Office (NAO) found the government 'remains a long way' from achieving its aim of containing and controlling AMR. Of five domestic targets set in 2019, just one – to reduce antibiotic use in livestock – has been met. Drug-resistant infections in Britain have increased by 13 per cent since 2018, despite a target to reduce them by 10 per cent, the NAO said. The decision to close the Fleming Fund was made quietly in February by the Labour government and revealed by the Telegraph in July. Fleming Fund money – used to run laboratories, train medical staff, test for resistant infections in hospitals, and share genetic information about mutant bacteria and viruses to global databases – will now run out in March 2026, despite assurances from the government it would be stretch at least another two years, a source with close knowledge of the project told The Telegraph. The source added that the Fleming Fund would have been able to continue functioning with half or even a quarter of its initial financial allocation by the Department of Health and Social Care (DHSC), but simply 'cannot operate with £0.' At a meeting on AMR at the UN General Assembly in New York only last year, Foreign Secretary David Lammy used the Fleming Fund to burnish the country's reputation abroad. He said: 'The UK is working with partners around the world, including through our existing Fleming Fund' in order to 'modernise our approach to development, rooted in a spirit of genuine partnership.' During a parliamentary evidence session in July, Ashley Dalton, Under-Secretary of State for Public Health and Prevention in the Department of Health and Social Care, said despite the decision to axe the fund's funding, the government will continue with its 'partnerships' forged under the Fleming Fund, although did not clarify what this meant. But Ben Simms, CEO of Global Health Partnerships, an organisation which trains and educates health workers in Africa and Asia and whose work is partly funded by the Fleming Fund, told The Telegraph that it was not clear if funding would continue. 'We can see that there is an aspiration to continue [the fund], but it just doesn't look credible at the moment, because there are no financial figures accompanying the aspiration to maintain partnerships, or any financial commitment to maintain a significant contribution on AMR,' Mr Simmons said. Experts have long emphasised that antibiotic resistant infections do not respect borders, and mitigating their spread around the world is vital to safeguard Britain's own health security. Lord O'Neil's 2014 Review concluded that in addition to millions of deaths, there would be massive economic consequences unless AMR was successfully dealt with. 'We projected that the lost economic potential due to AMR between 2015 and 2050 could be a staggering $100 trillion,' he said at the time.
